Announcements Trials
Browse Landscape

Phase

Phase 1 18Phase 2 3Phase 3 1

Status

Completed 3Terminated 2Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Neoplasm, Residual 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 280Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Completed × pevonedistat × Clear all
NCT04266795 2025-10-21

PEVENAZA

Takeda

Phase 2 Completed
164 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04712942 2023-08-21

Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat

University of Leipzig

Phase 2 Completed
14 enrolled
Myeloid

Myelodysplastic Syndromes, Neoplasm, Residual

NCT02610777 2022-09-19

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Takeda

Phase 2 Completed
120 enrolled 39 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡